real peptides FAQ

Use a medical-grade insulin cooler or temperature-controlled transport case that maintains 2–8°C for the full transport duration. Standard ice packs don't work. They freeze at 0°C, and direct contact with frozen surfaces can cause localized freezing of the peptide solution, which triggers ice crystal formation that ruptures peptide structures irreversibly. FRIO cooling wallets, which use evaporative cooling to maintain 18–26°C, are insufficient for tesofensine. The compound requires true refrigeration temperatures, not ambient-cool temperatures. If you lack proper transport equipment, it's better to reconstitute a fresh vial at your destination than risk 6–8 hours of temperature excursion with an already-reconstituted sample.

Run a pilot experiment comparing stored peptide against fresh reference before committing to a full study. Reconstitute stored TB-4 and fresh TB-4 at identical concentrations, then run a simplified version of your primary assay (single-plate scratch assay, single-animal pilot dose, etc.). If results differ by more than 15%, your stored peptide likely degraded. The cost of this verification step. One additional vial and one day of bench work. Is trivial compared to three months of inconclusive data from compromised peptide stock.

Discard it. Benzyl alcohol's preservative efficacy is temperature-dependent, and even a single overnight excursion above 8°C can allow bacterial growth to begin. The 2012 University of Iowa study found that vials stored at room temperature for just 24 hours showed measurable increases in bacterial colony counts compared to refrigerated controls. There's no reliable way to test for contamination at home. And the cost of the vial is negligible compared to the risk of injecting a contaminated solution into reconstituted peptides. Replace the vial rather than guess.

Do not use the peptide for any further dosing in the current study cohort. A 2-hour excursion to 15°C causes measurable but incomplete denaturation. The solution retains 70–85% potency, which creates result variance that can't be statistically controlled. Document the excursion timestamp, discard the affected vial, and replace it with a new one from a different batch. If the excursion occurred mid-study, note it in your methods section and analyse that animal's data separately. Reviewers will accept the variance if it's documented and excluded; they'll reject the study if undocumented variance skews your overall findings.

Run the assay anyway, but label results as partial characterization. GLP-1R activity alone tells you appetite suppression and insulin sensitization potential, but you're missing the hepatic lipid oxidation mechanism entirely. If the research question involves metabolic syndrome or fatty liver models, incomplete receptor coverage undermines the findings. Consider co-transfecting GCGR into your existing cell line or sourcing pre-validated dual-receptor CHO cells from ATCC or Millipore.

Yes, but only if you can deplete it within 35 days maximum. At 0.2ml daily, a 30ml vial lasts approximately 150 days. Far beyond the bacteriostatic stability window. The correct approach is splitting the 30ml into six 5ml sterile aliquots immediately post-reconstitution using aseptic transfer technique, then storing five aliquots frozen at −20°C. Thaw one aliquot at a time as needed. This preserves potency but requires lab-grade equipment and sterile vial blanks.

TB-4 shows limited efficacy in chronic inflammation models unless administered continuously at elevated doses. Chronic inflammation involves sustained cytokine expression at lower levels than acute injury. TB-4's transient NF-κB inhibition doesn't shift the baseline inflammatory set-point meaningfully when cytokine production is constitutive rather than injury-triggered. BPC-157 demonstrates superior outcomes in chronic inflammatory cartilage models due to systemic anti-inflammatory effects and gut-joint axis modulation that TB-4 doesn't address.

Increase vitamin C co-administration to 1500mg per 500mg GSH dose and verify you're using reduced (not oxidised) glutathione. Check formulation labels for 'L-glutathione reduced' or 'GSH'. If the label only says 'glutathione', it's likely oxidised form. Consider switching to liposomal delivery if you're using standard capsules. The 2017 Filipino cohort study found that non-responders at week 8 showed improved response when vitamin C dosing was increased from 250mg to 1000mg alongside the same GSH dose.

Daily dosing doesn't improve recomp outcomes and significantly increases cost. TB-4's tissue retention extends 3–4 days after a single injection because the peptide binds to G-actin and remains active in muscle and connective tissue. Plasma half-life (2–3 hours) is irrelevant here. What matters is tissue-level availability during recovery windows. A 2mg dose administered Monday and Thursday maintains sufficient actin-bound TB-4 throughout the week. Daily dosing at lower per-injection amounts (500mcg–1mg) might maintain more stable plasma levels, but there's no evidence this translates to better angiogenesis, collagen synthesis, or recovery capacity. Save the extra injections. Frequency doesn't compound the mechanism.

Discard it immediately. The 28-day usage window after first puncture is based on benzyl alcohol's antimicrobial concentration threshold. After 56 days at room temperature, preservative efficacy is compromised regardless of whether visible contamination appears. Bacterial growth may be subclinical (below the threshold for cloudiness) but still sufficient to degrade peptides in solution.

Check freezer temperature immediately upon power restoration. If internal temperature rose above −10°C for more than 4 hours, peptide potency is likely compromised by 15–30%. If temperature remained between −10°C and −20°C, integrity may be preserved but cannot be guaranteed without third-party potency testing. If temperature rose above 0°C (thawing occurred), discard the peptide. Partial thawing followed by refreezing causes ice crystal damage even in lyophilised form. Installing a freezer alarm system or using a laboratory unit with battery backup prevents this scenario entirely. Our team has seen multi-month studies invalidated by a single undetected outage.

Exclude subjects using combined oral contraceptives, hormonal IUDs, or depot injections from TB-4 research menstrual cycle studies. Exogenous hormones suppress endogenous estradiol and progesterone fluctuations entirely, eliminating the cycle-dependent variation the research aims to measure. Subjects using copper (non-hormonal) IUDs retain natural cycles and can be included. If contraceptive users must be analyzed, classify them as a separate group with 'suppressed ovarian function' rather than attempting to assign them to follicular or luteal categories.

Discard them. Visible aggregation or yellowing indicates advanced oxidation or moisture intrusion. Both irreversible. TB-4 oxidation occurs primarily at methionine residues, and once aggregated, the peptide will not redissolve properly even with extended mixing. Reconstituting degraded peptide produces inconsistent concentrations and introduces artifacts into your data. If you're unsure whether discolouration is from the vial label or the peptide itself, transfer the vial to bright overhead light and inspect through the glass. Pure lyophilised TB-4 is white to off-white; any yellow, brown, or grey tint is a reject signal.

Melanin synthesis resumes at baseline rates within 4–8 weeks of discontinuing glutathione, meaning skin tone gradually returns to pre-protocol levels over 3–6 months. This isn't rebound hyperpigmentation. It's normal melanocyte function reasserting. Some practitioners recommend tapering to a maintenance dose (250mg daily) rather than full discontinuation to sustain partial tyrosinase inhibition.

Dosing above 500mcg in GABAergic-sensitive individuals produces paradoxical sedation in roughly 18% of subjects. The enkephalin pathway Selank extends interacts with mu-opioid receptors, which can cause drowsiness when activated excessively. Reduce dose to 150–200mcg and administer only in the morning. Not split-dose. If drowsiness persists at reduced dose, Selank may not be appropriate for that research cohort. The alternative: NA-Selank (N-acetyl Selank), which has reduced opioid receptor affinity and lower sedation rates, though it's less widely studied.

Discard the vial immediately. Do not attempt reconstitution. Lyophilised tesofensine should appear as a uniform white or off-white powder with a smooth, compressed appearance. Clumping indicates moisture intrusion during storage, which triggers partial hydrolysis and aggregation before you ever add solvent. Discoloration (yellow, brown, or gray tones) signals oxidative degradation, likely from improper storage temperature or light exposure during shipping. Neither visual defect is reversible through reconstitution technique. The peptide structure is already compromised. Real Peptides replaces defective vials as a matter of quality assurance protocol; using degraded starting material guarantees poor results regardless of technique precision.

Check reconstitution and storage. High replicate variability (>20% coefficient of variation) in a well-controlled in vivo model almost always traces back to peptide handling. If some animals received peptide from an aliquot thawed 3 days ago and others from a fresh aliquot, activity differences will look like biological noise. Re-run with strict single-thaw aliquot discipline before concluding the peptide itself is inconsistent.

Cloudiness appearing 48+ hours post-reconstitution typically indicates bacterial contamination, not peptide degradation. Tesofensine degradation products remain in solution. They don't cause visible turbidity. Bacterial growth produces cloudiness because microbial cell density increases to levels visible to the naked eye (>10^7 CFU/mL). Check the vial for other contamination signs: gas bubbles forming spontaneously, color change, or unusual odor when the stopper is removed. If any are present, discard immediately. If cloudiness is the only symptom, you likely introduced bacteria during a subsequent draw rather than during initial reconstitution. Prevent this by using a fresh alcohol pad before every needle insertion and allowing 15–20 seconds of evaporation time before piercing the stopper.

Administer the missed dose as soon as you remember if it's within 12 hours of your usual injection time, then resume the regular schedule the next day. If more than 12 hours have passed, skip the missed dose entirely and continue with the next scheduled injection. Do not double-dose to 'catch up', as this increases the risk of headache and transient blood pressure elevation without improving outcomes. Missing 1–2 doses during a 20-day cycle does not invalidate the protocol, but missing more than 3 doses reduces cumulative BDNF upregulation below the threshold required for measurable cognitive changes. If you miss 4+ doses, restart the 20-day cycle from day one after a 7-day washout.

Administer TB-4 at least 12 hours before cognitive assessments to allow REM architecture to return to baseline—TB-4's 2.5-hour half-life means receptor modulation effects dissipate within 8–10 hours. Alternatively, split your study cohort into AM-dosed and PM-dosed groups and compare cognitive outcomes between them; if PM-dosed subjects show disproportionate improvements, sleep modulation is likely driving the effect rather than TB-4's primary mechanism. This approach isolates the confounding variable without requiring polysomnography equipment in every testing session.